| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Sinovac Biotech Ltd
13D/A
SVA · P8696W104
|
32.3% |
9/12/2025
Event 9/10/2025
|
||||
| 1Globe Capital LLC | 32.3% | |||||
| 1Globe Biomedical (Hong Kong) Company Limited | 32.3% | |||||
| Jiaqiang Li | 32.3% | |||||
| Schedule 13G · 1 security · passive | ||||||
|
Crescent Biopharma, Inc.
13G/A
CBIO · 38000Q201
|
10.3% |
10/14/2025
Event 10/7/2025
|
||||
| 1Globe Capital LLC | 10.3% | |||||
| Jiaqiang Li | 10.3% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.